Cyteir Therapeutics Advances Clinical Trial of Lead RAD51 Synthetic Lethality Program in Cancer and Expands Senior Leadership Team

2020-07-07T13:09:13-04:00

Cyteir Therapeutics Advances Clinical Trial of Lead RAD51 Synthetic Lethality Program in Cancer and Expands Senior Leadership Team Phase 1/2 study of first-in-class inhibitor of RAD51-mediated homologous recombination advancing to once-daily dosing Secrist, Gengos and Englert join Cyteir leadership team, enhancing company’s scientific, strategic business development, and drug development expertise LEXINGTON, Mass., July 7, [...]